Skip to content

Testosterone: What the Evidence Actually Shows

Last updated

Written and fact-checked by the Hormone Hero editorial team against the sources listed below. Not yet reviewed by a licensed clinician. How we work

Strong evidence · 5 sources

Multiple high-quality trials, systematic reviews, or clinical guidelines agree. Further research is unlikely to overturn the conclusion. How we grade evidence

Testosterone is the most oversold and most misunderstood hormone in consumer health. It genuinely helps some people with specific, diagnosable conditions. It is also marketed aggressively to people whose evidence base does not support it. This hub separates those two things.

Start here

What testosterone does

Testosterone is an androgen produced mainly in the testes in men and in the ovaries and adrenal glands in women. It contributes to sexual desire and function, muscle protein synthesis, bone mineral density, red blood cell production, and body fat distribution. It is present and biologically necessary in both sexes, at concentrations roughly ten to twenty times higher in men.

Levels decline gradually with age in both sexes. In men this is typically about one percent per year after the thirties, which is slow enough that most men never develop symptoms attributable to it. In women the decline is gradual and, importantly, is not driven by menopause itself the way estrogen loss is.

The recurring problem: symptoms are non-specific

Fatigue, low libido, poor concentration, weight gain, low mood, and disturbed sleep are the symptoms most often attributed to low testosterone. They are also the symptoms of sleep apnea, depression, thyroid disease, anemia, iron deficiency, chronic stress, medication side effects, and simply not sleeping enough.

This overlap is what makes the field so easy to market into. A symptom checklist that asks whether you are tired and less interested in sex will identify a very large fraction of adults, most of whom do not have a testosterone problem. Guidelines exist precisely to prevent that checklist from becoming a diagnosis.

Where the evidence is strong, and where it is not

ClaimWhat the evidence supports
Improves sexual function in men with diagnosed hypogonadismWell supported by randomized trials3
Improves sexual desire in postmenopausal women with HSDDSupported by meta-analysis and international consensus24
Does not meaningfully increase major cardiac events in men with hypogonadismSupported by a large dedicated safety trial5
Improves energy and vitalityNot supported. The trial designed to test this found no significant benefit3
Improves mood, cognition, or bone density in womenNot supported by current evidence4
Appropriate for age-related decline without diagnosed hypogonadismRecommended against by guideline1

Testing, in one paragraph

Testosterone should be measured on a fasting morning blood draw, and confirmed on a second separate morning before any diagnosis is made, because levels follow a daily rhythm and vary substantially day to day.1 When SHBG is likely abnormal, free testosterone measured by an accurate method is more informative than total. In women, standard assays are poorly calibrated to the low concentrations involved, and no cut-off defines deficiency.4

Questions worth asking before you start anything

  • Have I been tested twice, on separate mornings, fasting?
  • Have reversible causes been ruled out: sleep apnea, thyroid, anemia, medications, significant weight change?
  • What exactly is the diagnosis, and does it match a guideline definition?
  • What is the monitoring plan, and what would make us stop?
  • For men: has fertility been discussed? For women: how is a female-appropriate dose achieved and verified?

The bottom line

Properly diagnosed hypogonadism in men and HSDD in postmenopausal women are real conditions with real, evidence-supported treatment. Being tired in your forties is not, by itself, either of them. The most useful thing this hub can tell you is where that line sits, because almost nobody selling testosterone has an incentive to draw it clearly.

References

  1. Bhasin S, Brito JP, Cunningham GR, et al.. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 2018. Clinical practice guideline PMID: 29562364
  2. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes & Endocrinology 2019. Systematic review / meta-analysis PMID: 31353194
  3. Snyder PJ, Bhasin S, Cunningham GR, et al.. Effects of Testosterone Treatment in Older Men. New England Journal of Medicine 2016. Randomized controlled trial PMID: 26886521
  4. Davis SR, Baber R, Panay N, et al.. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. The Journal of Clinical Endocrinology & Metabolism 2019. Clinical practice guideline PMID: 31498871
  5. Lincoff AM, Bhasin S, Flevaris P, et al.. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine 2023. Randomized controlled trial PMID: 37326322